Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RDHL | 6-K | neutral | 5/10 | No summary provided | Aug 6, 2026 |
| CGON | PRESS-RELEASE | bearish | 7/10 | CG Oncology reported Q2 2026 EPS of -$0.90, significantly wider than the consensus estimate of -$0.64 (a 40.6% miss), wi | Aug 6, 2026 |
| DARE | PRESS-RELEASE | neutral | 1/10 | Daré Bioscience, Inc. announced it will host a conference call on August 13, 2026 to discuss its Q2 2026 results. | Aug 6, 2026 |
| CGON | 424B5 | bearish | 6/10 | CG Oncology upsized its at-the-market (ATM) equity offering by $500M to a total of $1.05B, after already selling $550M i | Aug 6, 2026 |
| CMPX | PRESS-RELEASE | bullish | 7/10 | Compass Therapeutics reported Q2 2026 net loss of $25.2M ($0.13/share), wider than the $19.9M loss in Q2 2025, driven by | Aug 6, 2026 |
| LXRX | PRESS-RELEASE | neutral | 5/10 | Lexicon Pharmaceuticals reported Q2 2026 revenue of $0.7M, down 97.6% from $28.9M a year ago due to the absence of a $27 | Aug 6, 2026 |
| AMTX | PRESS-RELEASE | bearish | 7/10 | Aemetis reported Q2 2026 revenue of $62.7M, up 20% YoY, and operating income of $5.8M versus a $10.7M loss a year ago, d | Aug 6, 2026 |
| ADCT | PRESS-RELEASE | neutral | 1/10 | ADC Therapeutics SA announced it will host a conference call on August 13, 2026 to discuss its Q2 2026 results. | Aug 6, 2026 |
| COLL | 8-K | mixed | 6/10 | Collegium reported Q2 2026 adjusted EPS of $1.92, beating the Street consensus of $1.48 by 29.7%, and revenue of $199.9M | Aug 6, 2026 |
| LGND | 8-K | bullish | 7/10 | Ligand reported Q2 2026 adjusted EPS of $2.37, a 20.3% beat vs consensus of $1.97, driven by 32% YoY royalty revenue gro | Aug 6, 2026 |
| LXRX | 8-K | neutral | 5/10 | Lexicon Pharmaceuticals reported Q2 2026 total revenue of $0.7M, a sharp decline from $28.9M in Q2 2025 which included a | Aug 6, 2026 |
| CLYM | 8-K | neutral | 4/10 | Climb Bio reported Q2 2026 results with a net loss of $13.5M ($0.18 loss per share), beating consensus of $0.22 by 18%. | Aug 6, 2026 |
| PEPG | 8-K | bullish | 7/10 | PepGen reported Q2 2026 EPS of -$0.26, beating the -$0.30 consensus by 13.3%, with no revenue. The key catalyst is the D | Aug 6, 2026 |
| NTLA | 8-K | mixed | 6/10 | Intellia Therapeutics reported Q2 2026 results with a net loss of $106.6M (-$0.80 EPS, -2.6% miss vs consensus) and coll | Aug 6, 2026 |
| LNTH | 8-K | bullish | 8/10 | Lantheus reported Q2 2026 revenue of $388.2M (+2.7% YoY) and GAAP EPS of $1.11, roughly in line with the $1.11 Street co | Aug 6, 2026 |
| CMND | PRESS-RELEASE | bullish | 6/10 | Clearmind Medicine received unanimous DSMB approval to advance its Phase I/II trial of CMND-100 for Alcohol Use Disorder | Aug 6, 2026 |
| VTRS | 8-K | bullish | 7/10 | Viatris Q2 2026 earnings beat consensus with adjusted EPS of $0.69 (15% above $0.60 est) and total revenue of $3.76B (+5 | Aug 6, 2026 |
| AGEN | 8-K | neutral | 5/10 | Agenus reported Q2 2026 total revenue of $34.5M (up 34% YoY from $25.7M), driven by $6.4M in pre-commercial BOT+BAL prod | Aug 6, 2026 |
| ANNX | PRESS-RELEASE | bullish | 7/10 | Annexon announced early positive data from the FORWARD open-label study of tanruprubart in Guillain-Barré syndrome (GBS) | Aug 6, 2026 |
| PCRX | PRESS-RELEASE | bullish | 6/10 | Pacira BioSciences reported positive two-year Phase 1 data for PCRX-201, a gene therapy for knee osteoarthritis, publish | Aug 6, 2026 |
| ASND | PRESS-RELEASE | bullish | 7/10 | Ascendis Pharma released positive Phase 2 COACH trial data showing its TransCon CNP + TransCon hGH combination therapy m | Aug 6, 2026 |
| ARGX | PRESS-RELEASE | bullish | 7/10 | argenx has commenced a tender offer to acquire all outstanding shares of Forte Biosciences for $77.00 per share in cash, | Aug 6, 2026 |
| TARS | 8-K | mixed | 6/10 | Tarsus Pharmaceuticals announced an oversubscribed $125.0 million PIPE financing concurrent with its pending acquisition | Aug 6, 2026 |
| ALGS | 8-K | mixed | 5/10 | Aligos Therapeutics reported Q2 2026 financial results with a net loss of $1.5M ($-0.14/share), a significant improvemen | Aug 6, 2026 |
| RNAC | 8-K | neutral | 4/10 | Cartesian Therapeutics reported Q2 2026 GAAP net income of $15.8M ($0.47 basic EPS), compared to net income of $15.9M ($ | Aug 6, 2026 |
| TARS | 8-K | bullish | 7/10 | Tarsus Pharmaceuticals announced a definitive agreement to acquire Alkeus Pharmaceuticals for ~$450M upfront ($270M cash | Aug 6, 2026 |
| GLUE | 8-K | neutral | 5/10 | Monte Rosa Therapeutics reported Q2 2026 results with collaboration revenue of $9.0M (down 61% YoY from $23.2M) and a ne | Aug 6, 2026 |
| PHVS | PRESS-RELEASE | neutral | 4/10 | Pharvaris announced publication of the first in-depth qualitative study in AAE-C1INH in Frontiers in Immunology, validat | Aug 6, 2026 |
| TARS | PRESS-RELEASE | neutral | 6/10 | Tarsus acquires Alkeus Pharmaceuticals for $450M upfront plus up to $350M in milestones, adding the Phase 3 Stargardt di | Aug 6, 2026 |
| KRRO | 8-K | bullish | 6/10 | Korro Bio reported Q2 2026 results with a net loss of $18.9M ($1.07/share) vs $25.8M ($2.74/share) in Q2 2025, with cash | Aug 6, 2026 |